NCT06867146View on ClinicalTrials.gov

MRD in PAAD Adjuvant Therapy

NAActive, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 15, 2024

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2027

Conditions
The Role of Molecular Residual Disease in the Treatment Strategy and Prognosis Prediction of Pancreatic Cancer Patients Undergoing Adjuvant TherapyMolecular Residual DiseasePancreatic CancerAdjuvant Therapy
Interventions
DRUG

Three-drug chemotherapy group

Three-drug chemotherapy group, mFOLFIRINOX, including 5-fluorouracil, leucovorin, oxaliplatin and irinotecan.

DRUG

two-drug chemotherapy group

two-drug chemotherapy group, including gemcitabine-based combination regimens (predominately gemcitabine/nab-paclitaxel or gemcitabine/capecitabine)

Trial Locations (1)

100730

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER

NCT06867146 - MRD in PAAD Adjuvant Therapy | Biotech Hunter | Biotech Hunter